Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab and Erlotinib in Neuroendocrine Tumors
NCT00947167Phase 2Terminated
- Start
- Mar 2009
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab in Neuroendocrine Neoplasm (NEN). Started Mar 2009; status: terminated.
02
Drugs
pertuzumab
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00947167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00947167.